Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Down 16.3% in January

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 7,804 shares, a drop of 16.3% from the December 31st total of 9,326 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 44,684 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 44,684 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.1% of the company’s stock are short sold.

Institutional Investors Weigh In On Lisata Therapeutics

Several hedge funds have recently bought and sold shares of LSTA. Cerity Partners LLC purchased a new position in shares of Lisata Therapeutics during the 2nd quarter valued at approximately $32,000. Ground Swell Capital LLC acquired a new stake in Lisata Therapeutics during the third quarter valued at $62,000. Finally, CIBC Bancorp USA Inc. purchased a new position in Lisata Therapeutics in the third quarter valued at $37,000. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Analysts Set New Price Targets

LSTA has been the topic of several recent research reports. Zacks Research cut Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Brookline Capital Management cut shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Lisata Therapeutics has an average rating of “Hold” and an average target price of $23.50.

Lisata Therapeutics Price Performance

LSTA traded up $0.13 on Wednesday, reaching $4.71. 217,107 shares of the stock were exchanged, compared to its average volume of 339,359. The company’s 50-day moving average price is $2.50 and its 200 day moving average price is $2.45. The firm has a market capitalization of $41.55 million, a PE ratio of -2.21 and a beta of 1.25. Lisata Therapeutics has a fifty-two week low of $1.81 and a fifty-two week high of $4.89.

Lisata Therapeutics (NASDAQ:LSTA) last released its earnings results on Thursday, November 6th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.05. As a group, equities analysts forecast that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.